Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Cancer cell·2026
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Fibroblasts hold the key to TLS formation.

Immunity·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026
Same author

Translating ctDNA into cutaneous melanoma care: An international expert survey.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: May 21, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Trial Watch: Adoptive cell transfer immunotherapy.

Lorenzo Galluzzi1, Erika Vacchelli, Alexander Eggermont

  • 1INSERM; U848; Villejuif, France ; Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France.

Oncoimmunology
|June 28, 2012
PubMed
Summary
This summary is machine-generated.

Adoptive cell transfer (ACT) activates a patient's own immune cells to fight cancer. This therapy shows durable regressions in melanoma and renal cell carcinoma, offering promise for other cancers.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

Related Experiment Videos

Last Updated: May 21, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Recent decades have seen advancements in cancer immunotherapy, including systemic agents and targeted therapies.
  • Adoptive cell transfer (ACT) is a promising cell-based therapy that involves ex vivo expansion and reinfusion of autologous anti-tumor lymphocytes.

Purpose of the Study:

  • To review the scientific rationale behind adoptive cell transfer (ACT) for cancer treatment.
  • To discuss the progress of recent clinical trials evaluating ACT's safety and efficacy.

Main Methods:

  • ACT involves isolating or generating autologous lymphocytes with anti-tumor activity.
  • These cells are expanded ex vivo, often with lymphodepleting regimens, and reinfused into patients.
  • Genetic engineering can enhance T-cell persistence, anti-tumor responses, and minimize side effects.

Main Results:

  • Adoptive cell transfer (ACT) has demonstrated a consistent rate of durable regressions in patients with melanoma and renal cell carcinoma.
  • The therapy holds significant promise for application in various other oncological settings.

Conclusions:

  • Adoptive cell transfer (ACT) represents a significant advancement in cancer immunotherapy.
  • Ongoing clinical trials are crucial for further evaluating the safety and effectiveness of ACT in diverse cancer types.